Intellia Therapeutics Inc (NTLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 4:41 PM ET
Intellia Therapeutics Inc (NTLA) Statistics
Intellia Therapeutics (NTLA) has a market cap of $1.36B and an enterprise value of $1.28B. It kept -805.75% of revenue as net income over the last 12 months. Its share count is up 27.22% from a year earlier.
Total Valuation
Enterprise value is 6.05% below the market cap, as cash exceeds debt.
| Market Cap | $1.36B |
|---|---|
| Enterprise Value | $1.28B |
| Latest price (Nov 17, 2026) | $9.78 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 25.9x and 2.2x. Its year-end P/S ranged from 4.2x to 255.7x from 2016 to 2025.
| P/S Ratio | 25.9x |
|---|---|
| Forward P/S | 31.4x |
| P/B Ratio | 2.2x |
Price Statistics
The stock is up 12.41% over 52 weeks and trades 17.12% below its 50-day average.
| Beta (1Y) | 2.32 |
|---|---|
| 52-Week Change | +12.41% |
| 1-Month Change | -15.54% |
| 3-Month Change | -26.36% |
| 6-Month Change | -18.09% |
| 5-Year Change | -90.62% |
| 10-Year Change | -9.51% |
| Total Return (1Y) | +12.41% |
| Total Return (3Y CAGR) | -29.67% |
| Total Return (5Y CAGR) | -40.86% |
| Return vs SPY (1Y) | +3.91% |
| Max Drawdown (1Y) | -45.63% |
| Max Drawdown (3Y) | -80.85% |
| Sharpe Ratio (1Y) | 0.19 |
| Correlation with SPY (1Y) | 0.43 |
| 50-Day Average | $11.80 |
| 200-Day Average | $12.92 |
| 52-Week Range | $7.95 to $18.48 |
| RSI (14 Days) | 37.3 |
| Average Volume (20 Days) | 4.63M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.31x current liabilities, and total debt is 0.12x shareholder equity.
| Current Ratio | 6.31x |
|---|---|
| Quick Ratio | 6.31x |
| Debt / Equity | 0.12x |
Returns and Efficiency
Return on invested capital is -50.04% over the last 12 months, against a 5-year average of -51.84%.
| Return on Equity (ROE) | -69.51% |
|---|---|
| Return on Assets (ROA) | -47.21% |
| Return on Invested Capital (ROIC) | -50.04% |
| ROE (5Y Average) | -46.19% |
| ROA (5Y Average) | -36.29% |
| ROIC (5Y Average) | -51.84% |
| Asset Turnover | 0.06x |
| Receivables Turnover | 7.14x |
Scores
NTLA has an Altman Z-Score of -2.65, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.65 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $52.89M over the last 12 months is down 8.07% from the 12 months before.
| Revenue | $52.89M |
|---|---|
| Revenue Growth (YoY) | -8.07% |
| Gross Profit | $52.89M |
| Operating Income | -$434.33M |
| Pretax Income | -$426.88M |
| Net Income | -$426.14M |
| EBITDA | -$425.35M |
| Reported EPS (TTM) | -$3.35 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 67.93% of the $902.56M in total assets.
| Cash and Equivalents | $156.10M |
|---|---|
| Total Debt | $73.73M |
| Net Cash | $82.37M |
| Net Cash Per Share | $0.59 |
| Working Capital | $426.04M |
| Shareholder Equity | $613.09M |
| Book Value Per Share | $4.37 |
| Total Assets | $902.56M |
| Total Liabilities | $289.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.90M of capital spending, operating cash flow left -$358.08M of free cash flow.
| Operating Cash Flow | -$355.17M |
|---|---|
| Capital Expenditures | $2.90M |
| Free Cash Flow | -$358.08M |
| FCF Per Share | -$2.56 |
| Depreciation and Amortization | $13.06M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -821.24%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -821.24% |
| Pretax Margin | -807.16% |
| Net Margin | -805.75% |
| EBITDA Margin | -804.26% |
| FCF Margin | -677.06% |
Growth
Revenue grew 9.09% a year over 3 years.
| Revenue Growth (3Y CAGR) | +9.09% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.13% |
| Book Value Per Share Growth (2Y CAGR) | -26.95% |
| Tangible Book Per Share Growth (2Y CAGR) | -26.95% |
Dividends and Yields
NTLA does not pay a dividend. Its free cash flow yield is -26.12%.
| FCF Yield | -26.12% |
|---|---|
| Buyback Yield | -16.85% |
| Shareholder Yield | -16.85% |
Peer Position
Against 8 similar companies, NTLA has the 4th highest P/S.
P/S RatioPeer median 16.4x
ROICPeer median -29.73%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +18.14%
| P/S Ratio | 25.9x vs 16.4x median |
|---|---|
| ROIC | -50.04% vs -29.73% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -8.07% vs +18.14% median |
Analyst Forecast
Consensus estimates put revenue growth at 32.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +32.61% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NTLA
What is NTLA's market cap?
Intellia Therapeutics has a market cap of $1.36B. Its enterprise value, which adds debt and subtracts cash, is $1.28B.
How many shares of NTLA are outstanding?
Intellia Therapeutics has 140.19M shares outstanding. The count is up 27.22% from a year earlier.
Does NTLA pay a dividend?
No. Intellia Therapeutics does not pay a dividend.
How much debt does NTLA have?
Intellia Therapeutics has $73.73M of total debt and $156.10M of cash and equivalents, a net cash position of $82.37M.
NTLA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors